NO20091892L - Krystallinsk form av (3S)-3-(N-(N`-(2-tert-butylfenyl)oksamyl) alaninyl)amino-5-(2`,3`,5`,6`-tetrafluorfenoksy)-4 oksopentanoisk syre - Google Patents

Krystallinsk form av (3S)-3-(N-(N`-(2-tert-butylfenyl)oksamyl) alaninyl)amino-5-(2`,3`,5`,6`-tetrafluorfenoksy)-4 oksopentanoisk syre

Info

Publication number
NO20091892L
NO20091892L NO20091892A NO20091892A NO20091892L NO 20091892 L NO20091892 L NO 20091892L NO 20091892 A NO20091892 A NO 20091892A NO 20091892 A NO20091892 A NO 20091892A NO 20091892 L NO20091892 L NO 20091892L
Authority
NO
Norway
Prior art keywords
tetrafluorophenoxy
alaninyl
oxamyl
butylphenyl
tert
Prior art date
Application number
NO20091892A
Other languages
English (en)
Other versions
NO338908B1 (no
Inventor
Stuart Dimock
Eric Hagen
Jason Hanko
Original Assignee
Conatus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conatus Pharmaceuticals Inc filed Critical Conatus Pharmaceuticals Inc
Publication of NO20091892L publication Critical patent/NO20091892L/no
Publication of NO338908B1 publication Critical patent/NO338908B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Det beskrives krystallinske former av (3S)-3-[N-(N'-(2-tert-butylfenyl)oksamyl)-alaninyl]amino-5-(2',3',5',6'-tetrafluorfenoksy)-4-oksopentanoisk syre (se formel I). Oppfinnelsen beskriver videre farmasøytiske sammensetninger 5 omfattende slike krystallinske former og anvendelse av nevnte farmasøytiske sammensetninger og nevnte krystallinske former i behandling av forskjellige tilstander, fortrinnsvis for behandling av leverfibrose.
NO20091892A 2006-12-06 2009-05-14 Krystallinsk form av (3S)-3-(N-(N'-(2-tert-butylfenyl)oksamyl)alaninyl)amino-5-(2',3',5',6'`-tetrafluorfenoksy)-4 oksopentanoisk syre NO338908B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86874806P 2006-12-06 2006-12-06
PCT/IB2007/003900 WO2008068615A1 (en) 2006-12-06 2007-12-03 Crystalline forms of ( 3 s ) -3- [n- (n' - (2-tert-butylphenyl) oxamyl) alaninyl] amino-5- (2 ', 3 ', 5 ', 6 ' -tetrafluoro phenoxy) -4-0x0penta noic acid

Publications (2)

Publication Number Publication Date
NO20091892L true NO20091892L (no) 2009-06-17
NO338908B1 NO338908B1 (no) 2016-10-31

Family

ID=39205161

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091892A NO338908B1 (no) 2006-12-06 2009-05-14 Krystallinsk form av (3S)-3-(N-(N'-(2-tert-butylfenyl)oksamyl)alaninyl)amino-5-(2',3',5',6'`-tetrafluorfenoksy)-4 oksopentanoisk syre

Country Status (22)

Country Link
US (1) US7692038B2 (no)
EP (1) EP2091910B1 (no)
JP (1) JP5495787B2 (no)
KR (1) KR101125932B1 (no)
CN (3) CN103951583B (no)
AR (1) AR064809A1 (no)
AU (1) AU2007330478B2 (no)
CA (1) CA2669849C (no)
CL (1) CL2007003491A1 (no)
DK (1) DK2091910T3 (no)
ES (1) ES2524021T3 (no)
HN (1) HN2007000536A (no)
IL (1) IL198732A (no)
MX (1) MX2009006055A (no)
NO (1) NO338908B1 (no)
PA (1) PA8759501A1 (no)
PE (1) PE20081251A1 (no)
PL (1) PL2091910T3 (no)
PT (1) PT2091910E (no)
TW (1) TWI345466B (no)
UY (1) UY30758A1 (no)
WO (1) WO2008068615A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2607806T5 (es) * 2010-02-12 2024-10-07 Pfizer Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
CN103113405B (zh) * 2012-10-17 2016-03-02 上海日馨生物科技有限公司 苯磷硫胺多晶型体、制备方法及其应用
PH12021551647A1 (en) * 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
MX2016014731A (es) 2014-05-12 2017-05-04 Conatus Pharmaceuticals Inc Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
HUE056583T2 (hu) * 2014-09-08 2022-02-28 Pfizer 6-Karboxi-2-(3,5-diklórfenil)-benzoxazol kristályos szilárd formái
SG11201705924RA (en) 2015-01-30 2017-08-30 Biomed Valley Discoveries Inc CRYSTALLINE FORMS OF C<sb>21</sb>H<sb>22</sb>CI<sb>2</sb>N<sb>4</sb>O<sb>2</sb>
EP3265440A1 (en) 2015-03-06 2018-01-10 Concert Pharmaceuticals Inc. Deuterated emricasan
CN105017061B (zh) * 2015-07-07 2017-03-29 苏州富士莱医药股份有限公司 一种恩利卡生的合成方法
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
KR20180101418A (ko) 2015-12-31 2018-09-12 코나터스 파마슈티칼스, 인크. 간 질환의 치료에서의 카스파제 억제제의 사용 방법
MX2019003889A (es) 2016-10-05 2019-08-12 Novartis Ag Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.
CN113354708B (zh) * 2017-01-23 2024-05-14 正大天晴药业集团股份有限公司 作为Caspase抑制剂的联环化合物
WO2018172950A1 (en) * 2017-03-23 2018-09-27 Novartis Ag Anhydrous crystalline forms of sodium (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinolinecarboxylate
WO2018178129A1 (en) * 2017-03-30 2018-10-04 Merck Patent Gmbh Crystalline form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
AR114251A1 (es) * 2018-02-13 2020-08-12 Syngenta Participations Ag Formas cristalinas de n-[2-(2,4-diclorofenil)ciclobutil]-2-(trifluorometl)piridin-3-carboxamida
US11447497B2 (en) 2018-06-29 2022-09-20 Histogen, Inc. (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
AU2020231396B2 (en) 2019-03-07 2025-03-20 Nobo Medicine Inc. Caspase inhibitors and methods of use thereof
WO2021050580A1 (en) 2019-09-10 2021-03-18 Mirati Therapeutics, Inc. Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
CN111351780A (zh) * 2019-12-29 2020-06-30 中船重工（邯郸）派瑞特种气体有限公司 一种三氟甲基磺酰氟电解槽中电解液成分的分析方法
AU2021260964A1 (en) 2020-04-23 2022-12-01 Pinotbio, Inc. Composition for treating blood cancer using 4'-thio-5-aza-2'-deoxycytidine and uses thereof
BR112023001236A2 (pt) * 2020-07-23 2023-04-04 Southern Res Inst Polimorfos de 5-aza-4'-tio-2-desoxicitidina
WO2022123062A1 (en) 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients
KR102670554B1 (ko) 2022-01-04 2024-05-30 주식회사 이노보테라퓨틱스 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69217762T2 (de) * 1991-07-30 1997-10-09 Ajinomoto Kk Kristalle von N-(Trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
DE59307210D1 (de) * 1993-05-12 1997-10-02 Heumann Pharma Gmbh & Co Stabile und kristalline Form von Bezafibrat
US7053056B2 (en) * 1998-07-02 2006-05-30 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6197750B1 (en) * 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6544951B2 (en) * 1998-07-02 2003-04-08 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
GB9923933D0 (en) * 1999-10-08 1999-12-08 Smithkline Beecham Lab Novel pharmaceutical
JP4424728B2 (ja) * 2001-12-11 2010-03-03 杏林製薬株式会社 置換フェニルプロピオン酸誘導体の新規な安定結晶とその製法
EP1904100A1 (en) * 2005-07-11 2008-04-02 Pfizer Limited New combination of anti-madcam antibody and antifibrotic caspase inhibitor to treat liver fibrosis

Also Published As

Publication number Publication date
TWI345466B (en) 2011-07-21
ES2524021T3 (es) 2014-12-03
DK2091910T3 (en) 2014-12-01
WO2008068615A8 (en) 2009-05-28
PE20081251A1 (es) 2008-09-17
JP5495787B2 (ja) 2014-05-21
KR20090080113A (ko) 2009-07-23
CA2669849C (en) 2012-01-31
WO2008068615A1 (en) 2008-06-12
PL2091910T3 (pl) 2015-02-27
HK1200440A1 (zh) 2015-08-07
CN103923169B (zh) 2017-05-24
IL198732A0 (en) 2010-02-17
IL198732A (en) 2014-02-27
US20080249031A1 (en) 2008-10-09
JP2010511689A (ja) 2010-04-15
CN103951583B (zh) 2016-01-06
TW200833319A (en) 2008-08-16
KR101125932B1 (ko) 2012-03-22
AU2007330478A1 (en) 2008-06-12
EP2091910B1 (en) 2014-08-20
CN101573328A (zh) 2009-11-04
HK1199885A1 (zh) 2015-07-24
AR064809A1 (es) 2009-04-29
CN103923169A (zh) 2014-07-16
HK1138567A1 (en) 2010-08-27
CL2007003491A1 (es) 2008-06-20
CA2669849A1 (en) 2008-06-12
CN103951583A (zh) 2014-07-30
PA8759501A1 (es) 2009-04-23
CN101573328B (zh) 2014-04-02
US7692038B2 (en) 2010-04-06
EP2091910A1 (en) 2009-08-26
MX2009006055A (es) 2009-06-16
NO338908B1 (no) 2016-10-31
AU2007330478B2 (en) 2011-09-08
HN2007000536A (es) 2011-01-17
PT2091910E (pt) 2014-11-18
UY30758A1 (es) 2008-07-31

Similar Documents

Publication Publication Date Title
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
TW200833319A (en) Crystalline forms
NO20050741L (no) Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
UA88012C2 (uk) Похідні хіназоліндіону як інгібітори parp
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
WO2007084595A3 (en) Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
EP2423207A3 (en) 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors
NO20070445L (no) Pyrimidinderivater.
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20053794L (no) N-(1-benzyl-2-oxo-2-(1-piperazinyl) etyl)-1-piperidinkarboksamid-derivater og relaterte forbindelsers bruk som CGRP-antagonister for behandling av hodepine.
NO20092286L (no) Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
HRP20050933A2 (en) Organic compounds
ATE413388T1 (de) Muskarin antagonisten
SE0401970D0 (sv) Novel compounds
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
SE0403171D0 (sv) New compounds
WO2007117465A3 (en) Indazole compounds
BR0307071A (pt) ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
PT2049480E (pt) Derivados de 2-arilindole como inibidores da mpges-i
WO2006100081A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: CONATUS PHARMACEUTICALS INC, US

MM1K Lapsed by not paying the annual fees